LIVN

Waters Corporation reported Q3 2026 earnings of $4.1 per share, beating consensus estimates of $3.99, with revenues of $1.77 billion exceeding expectations by 0.81%. The company has consistently beaten estimates over the last four quarters.

However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Waters shares have gained 18.4% year-to-date versus the S&P 500's 10.2% gain.

ClearPoint Neuro reported a Q3 loss of $0.24 per share, beating expectations of $0.32 loss, but missed revenue estimates with $12.08 million versus consensus. The company has underperformed the S&P 500 by 41% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.